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Evaluation of cost per test of clinical biochemistry tests at 
Parirenyatwa Central Hospital Laboratory, Harare, Zimbabwe
L MAKUWAZA, C MUSARURWA, ZAR GOMO
Abstract
Objectives: To determine the cost per test for selected clinical biochemistry tests at Parirenyatwa Central 
Hospital, Harare, Zimbabwe.
Design: A retrospective study for the month January 2003. Cost analysis was based on a 'bottom-up' micro 
cost analysis technique.
Setting: Parirenyatwa Central Hospital Laboratory
Results: There was wide variation between the cost o f performing a test and the hospital fee schedule offered 
in payment. The greatest variation was obtained for low frequency tests and direct consumables accounted for 
61.2% of the total costs.
Conclusion: Laboratory tests are heavily subsidized and there is need to contain the escalating costs by 
adopting some aggressive cost recovery measures. Introduction o f systematic teaching o f health economics
in the colleges o f health sciences is also advocated.
Introduction
In many countries, including Zimbabwe, there is 
increasing concern at the high and increasing cost of 
providing quality healthcare to the community. 
Pathology services represent about 25% of this 
expenditure.1 However, little is known about the actual 
cost to the Pathology Department of performing any 
individual pathology service or test. The health care 
market in Zimbabwe is characterised by a dominant 
public sector in both provision and financing of health 
services. Hongoro and Kumaranayake estimated that, 
in 1993, about 92% of health services in the country 
were provided by public institutions.2
In Zimbabwe, the rise in the cost of providing 
pathology services has been further exacerbated by 
perennial foreign currency constraints. This has 
resulted in regular increases in the cost of laboratory 
consumables since most of these are imported. As 
pressure on scarce resources mounts, there is need for a 
greater focus on the use of cost and cost effectiveness 
information to guide policy formulation.
Cost efficiency is the primary financial performance 
indicator for non-profit pathology laboratories and cost 
accounting is a key tool for managers of such 
institutions as they seek to keep costs under control. 
Pathology cost analysis provides a., fiscal foundation 
that helps identify economical batch sizes; justify the 
adoption of new methods; determine optimum test 
frequency; analyse staff performance and instrument
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efficiency.3 Cost effectiveness analysis thus, enables 
the adoption of the cheapest techniques to meet defined 
quantifiable targets.
Traditionally the Parirenyatwa Central Hospital 
(PCH) laboratory (Harare, Zimbabwe) a public 
institution, is allocated a 'top-down' annual budget into 
which the demands of the service are squeezed. 
Unfortunately, pathology laboratories remain demand- 
led, with managers having little control over the 
increasing requirements of the clinical services for 
pathology services.4
There is a paucity of reports available in the literature 
on the secular trends in expense, productivity and 
utilisation of pathology services in Zimbabwe. Some 
relevant knowledge on cost information may be 
possessed by individual organisations but the 
accumulated data is often considered proprietary and is 
not presented in peer-reviewed publications. The 
objective of this study was to provide a 'snapshot in 
time' of the actual cost of performing selected clinical 
biochemistry tests at PCH laboratory. The obtained 
costs would then be compared with the prices on the 
Relative Value Schedule published by the National 
Association of Medical Aid Societies (NAMAS) and 
adopted by PCH to charge patients for pathology tests.
Materials and Methods
The costing study described in this report was carried 
out in the clinical biochemistry department at PCH.
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The study was carried out retrospectively for the month 
of January 2003. The department offers both 
emergency and routine diagnostic assays both of which 
are performed on a shared Beckman synchron CX5 
analyser (Beckman Instruments Inc, Brea, USA).
The department's test menu is varied but the present 
study was limited to the following routine serum 
assays; urea and electrolytes (UEs) panel; liver 
function profile; plasma glucose; lipid profile; cardiac 
profile; bone profile; amylase; uric acid (UA) and 
pseudocholinestrase (PCHE). Heads of departments, 
relevant administration and accounting staff provided 
data on test counts, salaries and material, equipment 
and institutional overhead costs. The cost analysis was 
based on a 'bottom-up' microcost analysis technique 
developed by Travers and Krochmal.5 Individual tests 
constituting a panel were costed separately.
General Principles.
Prime costs: These are defined as those that are 
necessarily and exclusively incurred in measuring a 
specific analyte and consist of direct material and direct 
labourexpenses.
Direct material expenses consist of expenditure for 
reagents and test associated consumables used to 
produce a test result. Built into these consumable costs 
per test, therefore, are the costs of calibration; controls; 
repeat analyses and priming.
Direct labour costs consisted of the total 
compensation required for personnel to perform all the 
pre-analytical, analytical and post analytical stages of a 
test procedure. Estimation of labour time per activity 
was calculated from timing studies as staff went about 
their duties. An average of two such studies was used to 
calculate the salary cost per test.
Indirect costs: These are costs that cannot be traced to a 
test (unit of output) or to a segment of the equipment or 
operational structure required to produce a test result. 
These include equipment related costs (incurred in 
purchasing, amortisation, installing and maintaining 
the equipment); indirect labour costs (total 
compensations for personnel involved in work that 
cannot be traced to any particular test e.g. messengers, 
accounting staff and supervisors); indirect consumable 
costs (analyser spares and common reagents) and 
institutional overhead costs (power, water, rent, phones 
and safety wear).
Indirect labour costs were shared with six other 
pathology departments using an allocation factor of
0.25 as was done for all shared moveable assets. An 
allocation factor of 0.1 was used to apportion 
institutional overheads to pathology services, 0.25 of 
which was allocated to clinical biochemistry. The 
clinical biochemistry totals for indirect costs were then 
shared equally among all tests done.
Capital depreciation in the health service has usually 
been defined by the opportunity for a replacement 
analyser. The amortisation period remains rather
haphazard and variable between pieces of equipment 
and between laboratories. In the present study, the life 
span of the analyser was put at 10 years.
Manufacturing costs: The cost of'manufacturing' a 
test result was calculated as the sum of the prime and 
indirect costs.
Results
The calculated co&s were converted to the US$ using 
the prevailing official exchange rate at the time of the 
study which was ZS824.00 to one US$. The Z$ was, 
however, trading for as much as Z$ 1 500.00 to the US$ 
on the parallel market. The figures are presented in both 
currencies.
The most frequently requested tests included the UEs 
panel (n = llll) , plasma glucose (n=468) and liver 
function profile (n=269) while the low frequency tests 
were lipid profile (n=26); UA (n=20); PCHE (n= 20); 
Amylase (n=7) and cardiac profile (n=7), (Table 1). 
These total counts excluded controls and calibrators.
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Table I: Parirenyatwa Hospital clinical chemistry costs per testZ$ (US$).
Test Num ber of 
req u ests
Total labour 
co s ts
Total d irect 
c o s ts
Total indirect 
c o s ts
Total c o s ts  p e r te s t
Glue 468 479.40 586.26 226.42 816.24(0.99)
N a 1217 180.08 215.13 226.42 441.55(0.54)
K 1179 180.08 215.01 226.42 441.43(0.54)
Urea 1111 180.08 251.66 226.42 478.08(0.58)
Creat 1051 180.08 208.57 226.42 434.99(0.53)
TP 304 132.52 163.69 226.42 390.11 (0.47)
Alb 391 132.52 155.69 226.42 382.11 (0.46)
TB il 298 132.52 308.67 226.42 535.09(0.65)
C B II 64 132.52 658.75 226.42 885.17(1.07)
ALP 269 132.52 210.53 226.42 436.95(0.53)
ALT 288 132.52 208.66 226.42 435.08(0.53)
A S T 282 132.52 209.23 226.42 435.65(0.53)
Ca 114 180.08 339.40 226.42 565.82 (0.69)
Mg 113 180.08 568.45 226.42 794.87(0.97)
Phos 113 180.08 231.88 226.42 458.30(0.56)
Amy 26 530.53 3362.38 226.42 3 588.80(4.36)
Trig 26 305.54 1232.68 226.42 1459.10(1.77)
Choi 32 305.54 860.26 226.42 1086.68(1.32)
UA 20 530.53 1369.08 226.42 1 595.50(1.94)
LD 20 305.54 793.97 226.42 1020.39(1.24)
CK 8 305.54 3056.99 226.42 3283.41(3.99)
HBD 7 305.54 2044.28 226.42 2270.70(2.76)
PCHE 20 530.531 6060.59 226.42 6287.01 (7.63)
Total 7418 6914.59 23311.79 5207.66 28519.45(34.61)
Table I shows the cost per test/profile for PCH. 
Albumin had the lowest cost while PCHE had the 
highest cost. The low frequency tests had a higher 
calculated cost per test in comparison with the high 
frequency tests. PCHE, a low frequency test, had the 
highest cost per test while albumin (high frequency) 
had the lowest cost per test. Singular requests such as 
amylase, glucose and PCHE had high direct labour 
costs compared to panel tests in which the direct labour 
time was shared equally between tests constituting the 
panel.
Figure I: Comparison o f costs with prices charged.
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LP: Lipid profile.
CP: Cardiac profile.
UP: Uric acid.
PCHE: Pseudocholinestrase. 
U&E: Urea and Electrolytes.
LET: Liver function tests.
Amy: Amylase.
BP: Bone profile.
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Figure I shows cost per test/profile and a comparison of 
the calculated cost per test/profile with the prices 
charged. There was very little correlation between the 
cost of performing a test and the government fee 
schedule offered in payment especially for the low 
frequency tests. The calculated cost per test range was 
ZS382.11 to Z$6 287.01 (US$ 0.46 to $7.63) compared 
to an actual price range of Z$367.00 to Z$637.00 
(US$0.45 to $0.77). The greatest variation occurred for 
the rarely performed tests such as PCHE, cardiac 
profile, UAand amylase. During the period of the study 
the department made a net deficit of Z$826 407.78 
(US$1 002.92). The greatest deficit occurred from 
glucose (Z$208 578.24) (US$253.13) and PCHE 
(Z$ 113 000.20) (US$137.14) whilst negligible gains 
were made from albumin (Z$23 357.46) (US$28.34) 
and from inorganic phosphate (Z$9 119.10) 
(US$11.07).
Figure II: Distribution of cost units as % o f total.
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Figure II shows the distribution of cost units expressed 
as a percentage of total cost. Overall, the highest costs 
were attributable to direct consumables (61.21% of 
total costs) whilst the least costs were incurred for
indirect consumables (2.67%) making a total of 
63.88% for consumable costs. Total labour costs 
constituted 22.27% with 18.36% going to direct labour. 
Reagents constituted the highest direct consumable 
costs. Amylase, creatine kinase, -hydroxybutyrate 
dehydrogenase, PCHE and UA had high reagent costs 
and consequently high direct consumable costs. The 
high frequency tests had relatively lower direct 
consumable costs when compared to low frequency 
tests.
Discussion
Reported pathology costing methods differ in detail but 
agree that total laboratory costs can be split into the 
direct and the indirect.4'7 We preferred the instrument 
cost accounting technique since the present study 
revolved on the one major analyser in use in the 
department.5
The practice of calculating individual test costs has 
been discouraged primarily on the basis of the need for 
frequent recalculations as input costs change. 
Reluctance to embark on costing studies stems from the 
mistaken belief that the amount of effort necessary for 
reliable costing is incommensurate with possible 
benefits. However, in present day hyperinflationary 
Zimbabwe, quotations for consumables are valid for 
short durations and regular salary reviews are the order 
of the day. Frequent recalculation of actual cost data, is 
therefore, desirable.
Total labour costs constituted a mere 22.27% of total 
costs, a proportion at variance with reports from other 
researchers who attribute over 50% of total costs to 
labour.78 This finding indicates that laboratory staff 
salaries are not keeping pace with inflation. Labour 
costs may, however, be reduced further by rationalising 
staff allocation per workstation, but such a move poses 
the risk of compromising work quality.
Direct consumable costs tended to increase with 
increasing reagent price. Both direct labour and direct 
consumable costs per test were lower for the panel tests 
than for singular requests. The higher costs for singular 
requests, could be reduced by avoiding multiple 
bleeding of the same patient and, where possible, 
including all relevant tests on one request. Further 
savings could be achieved by use of in-house 
consumables such as reagents, control and calibration 
material. Another option would be to purchase long- 
shelf-life reagents in bulk and to identify alternative 
cheaper methods. Staff should also be made aware of 
the actual costs of the various consumables if they are 
to contribute towards cost containment.
Low frequency tests were associated with a higher 
number o f non-chargeable tests (controls and 
calibrators) thus contributing to their high cost. 
Deleting from the repertoire uninformative tests and 
subcontracting the useful high cost low frequency tests 
to other laboratories could achieve effective savings. 
Batching of low frequency tests could also be adopted 
but that option could result in costly clinical delays in
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patient management.
The price schedule, although revised regularly, is 
largely a historical document in which the set fees bear 
little resemblance to the true cost of performing 
pathology services. Health service providers should 
regularly carry out comprehensive cost analysis 
studies, which would help strengthen their demands for 
fees adjustment. Our data demonstrates that laboratory 
tests are heavily subsidised. Each institution has its 
own unique test cost profile based on salary scales and 
workflow efficiency and practitioners should be 
encouraged to regularly calculate their cost data and 
institute appropriate cost containment measures as 
required.
Without good financial and activity information, 
laboratories risk falling prey to institutional 'gut 
feelings' of their being over-resourced, wasteful and 
self-indulgent. With good data at hand, pathology 
departments can demonstrate efficient management 
and patient care, and help plan and remain part of the 
future in their hospitals. This may start by adopting 
aggressive cost recovery measures and the introduction 
of systematic teaching of health economics in the 
colleges of health sciences.
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